Business
ARIUS Announces Third Quarter Fiscal 2007 Financial Results
ARIUS Announces Third Quarter Fiscal 2007 Financial Results.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\nTORONTO, Oct. 12 /CNW/ - ARIUS Research Inc., (TSX: ARI), a biotechnology\ncompany discovering and developing the next wave of antibody therapeutics,\ntoday announced its financial and operational results for the third quarter,\nended August 31, 2007.\n\n\n"Our third quarter of fiscal 2007 was one of preparation as we worked\ntowards moving our lead drug candidate AR001 into human clinical trials in\n2008, while also building value in our business and our pipeline through the\nprogression of our other antibody anti-cancer candidates," said Dr. David\nYoung, President and CEO. "Our most important development this quarter and a\nmilestone step for ARIUS, was the initiation of a pre-clinical dose-finding\ntoxicology study for AR001, our CD44 targeting anti-cancer antibody."\n\n\nProgram Updates:\n\n\nCD44 Cancer Stem Cell Program\n\n\nARIUS initiated a pre-clinical dose-finding study, commencing its\nIND-enabling toxicology program for its lead anti-CD44 antibody. The Company\nexpects to file a Phase I IND application and begin human clinical trials in\n2008. The Company engaged a manufacturer for process development and\nmanufacturing of its lead antibody under Current Good Manufacturing Practices\n("cGMP").\n\n\nTrop-2 Signal Transduction Program\n\n\nARIUS has successfully humanized its anti-Trop-2 antibody, which\ncontinues to retain its binding characteristics and in vivo activity. The\nCompany also selected a manufacturer for the antibody. The Company expects to\nperform pre-clinical toxicology studies in 2008 in preparation for filing a\nPhase I IND application in 2008.\n\n\nCD59 Complement Inhibitor Program\n\n\nIn collaboration with Antitope Limited, ARIUS has successfully humanized\nits CD59 targeting antibody, retaining its binding characteristics and in vivo\nactivity. The Company expects to perform preclinical toxicology studies in\n2008 in preparation for filing a Phase I IND application.\n\n\nCD63 Antibody Program\n\n\nThe Genentech-partnered CD63 antibody program continues to produce\nresults from further preclinical studies in a variety of cancer indications in\nits progress towards human clinical trials.\n\n\nTakeda Collaboration\n\n\nARIUS successfully met its year one obligations and received all\nscheduled research payments from Takeda.\n\n\nAdditional Product Updates\n\n\n...